Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Occup Health ; 47(4): 277-85, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16096351

RESUMO

Perfluoroisobutylene (PFIB) is a kind of fluoro-olefin that is ten times more toxic than phosgene. The mechanisms of the acute lung injury (ALI) induced by PFIB inhalation remain unclear. To find possible pharmacological interventions, mice and rats were exposed to PFIB, and the prophylactic or therapeutic effects of 3-quinuclidinyl benzilate (QNB) and anisodamine were studied and confirmed. It was observed that the wet lung/body weight and the dry lung/body weight ratios at 24 h after PFIB exposure (130 mg/m(3) for 5 min) were significantly decreased when a single dose of QNB (5 mg/kg) was administered intraperitoneally either 30 min before exposure or 10 h after exposure. Anisodamine was without any prophylactic or therapeutic effects at single doses below 30 mg/kg. The effects of QNB against PFIB inhalation induced ALI were well evidenced by the significantly decreased mice mortality at 72 h, the total protein concentration in bronchoalveolar lavage fluid at 24 h after the PFIB exposure, as well as the ultrastructural observations. The analysis of the time courses of lung sulfhydryl concentration, myeloperoxidase (MPO) activity and hemorheology assay showed that the toxicity of PFIB may be due to consumption of lung protein sulfhydryl, influx of polymorphonuclear leukocytes (PMNs) into the lung, and increased peripheral blood viscosity at a low shear rate, all of which were partially blocked by QNB intervention except for PMN influx. The results suggest that cholinolytics might have prophylactic and therapeutic roles in PFIB inhalation induced ALI.


Assuntos
Antagonistas Colinérgicos/uso terapêutico , Fluorocarbonos/toxicidade , Exposição por Inalação , Síndrome do Desconforto Respiratório/prevenção & controle , Animais , Peso Corporal/efeitos dos fármacos , China , Antagonistas Colinérgicos/administração & dosagem , Pulmão/ultraestrutura , Masculino , Camundongos , Exposição Ocupacional , Tamanho do Órgão/efeitos dos fármacos , Quinuclidinil Benzilato/administração & dosagem , Quinuclidinil Benzilato/efeitos adversos , Ratos , Ratos Wistar , Síndrome do Desconforto Respiratório/tratamento farmacológico , Síndrome do Desconforto Respiratório/fisiopatologia , Alcaloides de Solanáceas/administração & dosagem , Alcaloides de Solanáceas/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA